Implementation of a Pharmacist-Based, Post-Chemotherapy Follow-up Clinic

NCT05965206 | Completed

• 1 other identifier: Study00002683
• Study Type: observational
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to determine the impact of pharmacists on reducing chemotherapy-related side effects by providing education before and after patients receive intravenous chemotherapy at one of Cedars-Sinai outpatient infusion centers. Participants will be interviewed via telephone within 7 business days after receiving intravenous chemotherapy from the outpatient cancer center infusion clinic.

Conditions

Cancer

Keywords

Pharmacist; Follow up clinic

Outcome Measures

Primary Outcomes (1)

• Hospital admission related to chemotherapy within 30-day post treatment

  Number of hospital admission related to chemotherapy

  30 days after receiving the first intravenous chemotherapy

Study Arms (2)

Intervention group

Participants receive a follow-up phone call from a pharmacist approximately 7 business days after receiving intravenous chemotherapy infusion

Behavioral: Follow-up phone interview

Control group

Participants do not receive a follow-up phone call from a pharmacist after receiving intravenous chemotherapy infusion

Interventions

Follow-up phone interview BEHAVIORAL

Follow-up phone interview within 7 business days after receiving intravenous chemotherapy

Also known as: Follow-up call

Intervention group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult cancer patients who initiated treatment with intravenous chemotherapy

You may qualify if:

• At least 18 years old
• Diagnosed with cancer and is receiving treatment with intravenous chemotherapy
• Treatment initiated at Cedars-Sinai Cancer Samuel Oschin Cancer Center (SOCC) or Cedars-Sinai Cancer Beverly Hills (CSCBH)
• English-speaking or lives with English-speaking person
• Access to a working phone

You may not qualify if:

• Received follow-up calls through other specialty pharmacy program
• History of infusion related reactions
• Declined participation on follow-up interview
• Age less than 18 years old
• Non-English speaking
• Electronic health record flagged for research opt out

Sponsors & Collaborators

• Cedars-Sinai Medical Center: lead

Study Sites (1)

Cedars-Sinai Medical Center

Los Angeles, California, 90048, United States

Location

Related Publications (4)

• Patel SD, Nguyen PAA, Bachler M, Atkinson B. Implementation of postdischarge follow-up telephone calls at a comprehensive cancer center. Am J Health Syst Pharm. 2017 Jun 1;74(11 Supplement 2):S42-S46. doi: 10.2146/ajhp160805.

  PMID: 28506976 BACKGROUND

• Nguyen PAA, Enwere E, Gautreaux S, Lin H, Tverdek F, Lu M, Cao H, Chase J, Roux R. Impact of a pharmacy-driven transitions-of-care program on postdischarge healthcare utilization at a national comprehensive cancer center. Am J Health Syst Pharm. 2018 Sep 15;75(18):1386-1393. doi: 10.2146/ajhp170747. Epub 2018 Jul 31.

  PMID: 30065061 BACKGROUND

• Cebollero J, LaFollette JA, Walton SM, Adams Curry M. Evaluation of a Pharmacist-Developed, Nurse-Driven Protocol for Management of Parenteral Anticancer Therapy Infusion Reactions in an Ambulatory Infusion Center. J Oncol Pharm Pract. 2023 Jun;29(4):802-809. doi: 10.1177/10781552221079855. Epub 2022 Feb 14.

  PMID: 35164607 RESULT

• Crannage AJ, Hennessey EK, Challen LM, Stevens AM, Berry TM. Implementation of a Discharge Education Program to Improve Transitions of Care for Patients at High Risk of Medication Errors. Ann Pharmacother. 2020 Jun;54(6):561-566. doi: 10.1177/1060028019896377. Epub 2019 Dec 21.

  PMID: 31868004 RESULT

MeSH Terms

Conditions

Neoplasms

Study Officials

• Suwicha Limvorasak, PharmD

  Cedars-Sinai Medical Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: PharmD

Study Record Dates

• First Submitted: July 20, 2023
• First Posted: July 28, 2023
• Study Start: July 20, 2024
• Primary Completion: April 30, 2025
• Study Completion: April 30, 2025
• Last Updated: May 14, 2025

Record last verified: 2025-05

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)